(HealthDay News) — For critically ill patients undergoing mechanical ventilation for at least three days, a three-day course of inhaled amikacin reduces the subsequent burden of ventilatory-associated pneumonia, according to a study published online Oct. 25 in the New England Journal of Medicine. The study was published to coincide with the annual congress of the European Society of Intensive Care Medicine, held from Oct. 21 to 25 in Milan.
Stephan Ehrmann, MD, PhD, from the Centre Hospitalier Régional Universitaire de Tours in France, and colleagues conducted a multicenter superiority trial involving critically ill adults who had been undergoing invasive mechanical ventilation for at least 72 hours to receive inhaled amikacin once daily or placebo for three days (417 and 430 patients, respectively). Overall, 337 and 355 patients (81 and 82%) received all three daily nebulizations in the amikacin and placebo groups, respectively.
The researchers found that ventilator-associated pneumonia developed at day 28 in 15% of patients in the amikacin group and 22% in the placebo group (difference in restricted mean survival time to ventilator-associated pneumonia, 1.5 days). In 18 and 26% of the patients in the amikacin and placebo groups, respectively, an infection-related ventilator-associated complication occurred (hazard ratio, 0.66). Overall, 1.7% of patients in the amikacin group and 0.9% in the placebo group had trial-related serious adverse effects.
“In this large multicenter trial, a three-day course of amikacin reduced the burden of ventilator-associated pneumonia by day 28 as compared with placebo,” the authors write. “Results were consistent with regard to ventilator-associated events.”
Several authors disclosed ties to industry.
Abstract/Full Text (subscription or payment may be required)
